19 May 2023

2022 Annual Report and 2023 AGM Notice



Shield Therapeutics plc

("Shield" or the “Company" or the “Group”)


2022 Annual Report and 2023 AGM Notice


London, UK, 19 May 2023: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company focused on the commercialisation of its innovative oral iron therapy for iron deficiency, Accrufer®/Feraccru® (ferric maltol), announces that the following documents have now been sent to shareholders:


  • Annual Report and Accounts for the year ended 31 December 2022
  • Notice of Annual General Meeting ("AGM") 2023


In accordance with AIM Rule 26, these documents are also available to view on the Company's website: Results, Reports & Presentations | Shield Therapeutics plc.


This year the Company's AGM will be held at 2.00pm (BST) on 28 June 2023 at the offices of Shield Therapeutics plc, Northern Design Centre, Baltic Business Quarter, Gateshead Quays, England NE8 3DF. 


If you wish to attend the AGM in your capacity as a shareholder, please bring proof of shareholding or if shares are held through a nominee account, a letter of representation, to facilitate your entry to the Meeting.


The Company will provide a facility for shareholders to join the AGM online and telephonically and there will be an opportunity for shareholders to ask questions. In order to facilitate the process, the Board would request that shareholders register for the meeting and submit questions in advance, before 2.00pm (BST) on 26 June 2023.

To register for dial-in details and to submit any questions please contact Walbrook PR via email at shield@walbrookpr.com or call +44 (0)20 7933 8780.


For further information please contact:


Shield Therapeutics plc


Greg Madison, CEO

+44 (0) 191 511 8500

Hans-Peter Rudolf, CFO



Nominated Adviser and Joint Broker


Peel Hunt LLP


James Steel/Oliver Duckworth

+44 (0)20 7418 8900


Joint Broker

finnCap Ltd     

Geoff Nash/George Dollemore/Alice Lane/Nigel Birks/Harriet Ward                                            




+44 (0)20 7220 0500



Financial PR & IR Advisor


Walbrook PR


Paul McManus/Lianne Applegarth/Alice Woodings

+44 (0)20 7933 8780 or shield@walbrookpr.com



Investor Contact (US Advisor)

LifeSci Advisors, LLC

John Mullaly



+1 617 429 3548 or jmullaly@lifesciadvisors.com

Back to News